Tagrisso (AstraZeneca) is expected to face US generic competition from 2032. Some US patents expire 2032; the last listed patent runs to 2035.
Tagrisso's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a small-molecule drug, so copies are generics. Generic launches usually take most of the US volume within months.
Tagrisso is 12% of AstraZeneca's 2025 revenue ($7.3B of $58.7B). With Farxiga, the drugs tracked here add up to 27% of AstraZeneca's revenue losing US exclusivity by 2032.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Tagrisso is highlighted.